Skip to content

Comparison of two types of procedures for the treatment of facial pain

Radiofrequency thermoablation of the Gasserian ganglion versus peripheral nerve branches of trigeminal nerve for the treatment of ideopathic trigeminal neuralgia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/12/007576
Enrollment
50
Registered
2016-12-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Idiopathic Trigeminal Neuralgia

Interventions

Intervention1: Radiofrequency thermoablation of peripheral branches of trigeminal nerve: patients will receive radiofrequency thermoablation of peripheral branches of trigeminal nerve according to the

Sponsors

Post Graduate Institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Persistent trigeminal neuralgia pain for more than one month, which is not relieved by conventional medical therapy

Exclusion criteria

Exclusion criteria: • Injection site not suitable for intervention • Patients with unstable cardio-respiratory disorder • Coagulation & hematological disorder • Psychological disorder or history of drug abuse • Patients non-compliant for follow up

Design outcomes

Primary

MeasureTime frame
intensity of pain assessed by Neumarical rating scale and Barrow Neurological Institute pain intensity scaleTimepoint: at one week, two week, one month and three month post procedure

Secondary

MeasureTime frame
Any complication like dysesthesia, masseter weakness, cheek hematoma, cranial nerve paralysis and any neurological deficitTimepoint: Just post procedure and during follow up at 1 week, 2 week, 1 month and 3 month

Countries

India

Contacts

Public ContactNeerja Bharti

PGIMER

bhartineerja@yahoo.com9915575145

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026